A B S T R AC T
Objective: We sought to determine the validity of cancer antigen 125 (CA-125) and the risk of malignancy index (RMI) in the diagnosis of ovarian cancer in women presenting with adnexal lesions of various histopathology types. Methods: This retrospective crosssectional study included all women with adnexal lesions who were evaluated at the Royal Hospital, Oman, between January 2012 and December 2014. The inclusion criteria included women who underwent surgical intervention and who had preoperative CA-125 testing and pelvic ultrasound in the work-up plan of their management. The surgical intervention was usually followed by a histopathological diagnosis of the nature of the lesion, which was used as the gold standard for the evaluation of both CA-125 and RMI. Results: The cohort included 361 women who had serum CA-125 and pelvic ultrasound prior to the surgical intervention of the adnexal lesion. Of these women, 61 (17%) had malignant ovarian lesions. Using the proposed cut-off 35 U/ml for CA-125 and 200 for RMI, the CA-125 test was more sensitive for detecting the majority of malignant ovarian tumors compared to the RMI (69% vs. 57%). Both tests were more sensitive in detecting epithelial ovarian cancer compared to other ovarian cancers. However, RMI was more specific in excluding benign ovarian lesions compared to CA-125 (81% vs. 68%). Additionally, RMI had a better area under the curve compared to CA-125 (0.771 vs. 0.745; p<0.005). Lowering the RMI cut-off to 150 resulted in a better sensitivity (62% vs. 57%) and had an acceptable specificity (78% vs. 81%) compared to a cut-off of 200. Conclusion: Both CA-125 and RMI have good validity in the diagnosis of ovarian tumors. CA-125 has higher sensitivity; however, RMI has higher specificity. In combination, CA-125 might be more valid for the diagnosis of malignant ovarian cancer while RMI is more valid for excluding the diagnosis of these tumors. Differential use of these two tools will improve the triage of women with suspected ovarian tumors since both are measured in their work-up. We recommended the use of both tools in primary care to reduce referral to gynecology or oncology units.
it can also be elevated in some benign conditions of the ovary including ovarian endometrioma. 5 These findings were illustrated further by others who also reported a poor sensitivity and specificity when the test was used alone. 6 To improve the validity of CA-125, the risk of malignancy index (RMI) was developed by Jacobs et al 7 in 1990. The RMI uses a multimodality approach that combines the CA-125 result with ultrasound findings and menopausal state to calculate an index score that helps to predict the risk of ovarian cancer in women presenting with an adnexal mass. The RMI is widely used in the UK and has been recommended by NICE guidelines as a tool for screening high-risk women in the primary care setting. 8 The RMI was modified by Tingulstad et al, 9 in 1996 to the RMI 2. There are minor differences between the two indices in the evaluation of ultrasound and menopausal scoring. Both RMIs were assessed in a few studies with some favor towards the modified version. [10] [11] [12] The studies recommended the use of RMI in the primary care setting as it is a simple and cheap approach that can facilitate referral to specialized gynecological centers. A systematic review supported the usefulness of RMI in clinical practice as the test of choice in the preoperative evaluation of women with adnexal masses. 13 The aim of this study was to highlight the usefulness of RMI as a diagnostic tool for evaluating women with suspected ovarian tumors attending the gynecology department (outpatient clinic and wards) at the Royal Hospital, Oman, during a threeyear period. The study aimed to evaluate the validity of CA-125 alone as a currently used tumor marker and compare its performance with RMI. Although this study is not new in this field, it is the first in Oman where the use of CA-125 with or without RMI is not common practice by the primary care clinicians or gynecologists assessing women presenting with a suspected ovarian lesion or tumor.
M ET H O D S
This retrospective cross-sectional study looked at all operated cases of ovarian diseases performed at the Royal Hospital between January 2012 and December 2014. The study included all women who were referred to the gynecology department for the evaluation and management of an ovarian mass or disorder for which an ovarian operation/ biopsy was done and laboratory work-up, including measurement of serum CA-125 and pelvic ultrasound, were performed prior to surgery. All clinical and laboratory data were collected using the hospital information system (Al-Shifa 3 Plus).
The CA-125 assay was performed by a twostep immunoassay chemiluminescent microparticle immunoassay technology (Architect 2000i, Abbott, US). The assays followed the manufacturers recommendations for quality assessment (internal and external). The between run precisions as reflected by the coefficient of variation were 2.8%, 3.2%, and 2.2% for the three levels of internal quality control materials (low, middle, and high concentration of CA-125), respectively.
From the variables collected, the RMI was calculated based on the equation recommended by Tingulstad et al, 9 as follows:
Where U is the total ultrasound score, M is the menopausal status and the CA-125 value in U/ml. In this formula, a score was assigned for the ultrasonography characteristics looking for the presence of multilocular cystic lesions, solid areas, bilateral lesions, ascites, and intra-abdominal metastasis. A score of one was given if present. The total ultrasound score was calculated for each patient, where a total ultrasound score of zero or one was given a value of one and a score greater than two was given a U-score of four. The postmenopausal status was defined as one year or more of amenorrhea or aged 50 years or more if the woman had undergone a hysterectomy. The menopausal status score was one for premenopausal women and four for postmenopausal women. Finally, the value of serum CA-125 concentration was substituted directly into the formula. RMI 2 scoring was implemented and calculated for all women included in this study hence when RMI it is mentioned we are referring to RMI 2. The performance of the RMI scoring system will be presented in this cohort and its validity will be compared to CA-125 values based on the histopathology report of the ovarian lesion, which is considered as the gold standard in this validation study. The cut-off value for CA-125 of 35 U/ml was used as recommended by the manufacturer and internationally. A cut-off value of 200 for the RMI was followed as recommended by Jacobs et al, 7 to achieve relatively high levels of sensitivity and specificity.
SPSS Statistics (SPSS Inc., Chicago, US) was used to calculate the mean and standard deviation (SD). The non-parametric t-test, Kruskal-Wallis test, and Mann-Whitney U test were used to compare the differences in the means of each parameter (measured or calculated) between the different groups. Statistical significance was assigned to p<0.050.
The classification of the results for each parameter as normal or abnormal was based on the result of histopathology report versus the cutoffs used for CA-125 and RMI. Quality assurance for CA-125 was followed using both Internal QC (BIORAD, USA) and the External QA scheme (RIQAS, UK). The validity indicators (sensitivity, specificity, negative and positive predictive values, and efficiency) for CA-125 and MRI compared to the histopathology examination were calculated and compared at the recommended cut-offs. Receiver operator characteristic (ROC) and the area under the curve (AUC) for CA-125 and RMI were constructed to identify the preferred cut-off for both tools in our cohort.
R E SU LTS
The total number of ovarian biopsies/surgeries in the study period was 441. However, only 361 cases had complete data that included both CA-125 and ultrasound report prior to the intervention and only these were included in this evaluation study. Table 1 summarizes the demographic characteristics of the studied population, and the histological results of the examined ovarian specimens are given in Table 2 . The histopathology classifications of ovarian tumors included surface epithelial-stromal, sex cord-stromal, and germ cell tumors. Lesions that did not fit into these three groups were grouped as others.
Of the 441 ovarian specimens examined, 376 (85.3%) were benign, and 65 (14.7%) were malignant. The malignant tumors included epithelial tumors (49.2%), in which serous cystadenocarcinoma (20.0%) was predominant, followed by borderline epithelial tumors (16.9%). Germ cell tumor (18.5%) was the second common malignant type followed by sex cord tumor (13.8%). In contrast, the most common benign lesions were epithelial types (46.5%) followed by germ cell types (33.5%). Among these, the most common benign lesions were teratoma (32.7%) followed by endometriotic cysts (28.4%) and serous cystadenoma (14.1%).
The descriptive analysis for CA-125 and RMI in the benign and malignant ovarian tumor groups with the various histological lesions are shown in Table 3 . Both CA-125 and RMI were not normally distributed; hence non-parametric t-tests (KruskalWallis test and Mann-Whitney U test) were applied.
The validity indicators for CA-125 and RMI for diagnosing all malignant ovarian tumors and epithelial ovarian tumors, with and without borderline tumors, are shown in Table 4 . A high rate of false negative CA-125 and RMI results in patients with borderline epithelial lesions (5/11 and 7/11, respectively) and sex cord ovarian lesions (6/6 for both) was observed. Also, in patients with benign ovarian lesions, a different rate of true negative and false positive results were observed. A high proportion of false-positive CA-125 results (66/89) was noted in patients with endometriosis, with a median CA-125 of 144 U/ml (range 9-3044). In contrast, RMI showed a better performance in endometriosis with only 38/89 false positive results. Also, there were two patients with stage five chronic kidney disease (CKD) with eGFR <15 ml/min/1.73 m 2 , one had a hemorrhagic functional cyst (CA-125 was 104 U/ml) and the other had normal ovarian pathology but presented with ascites (CA-125 was 224 U/ml).
The ROC curves for both CA-125 and RMI are shown in Figure 1 . The AUC for CA-125 and RMI were 0.745 and 0.771, respectively, (p<0.001). The validity indicator for both CA-125 and RMI was checked at different cut-off points [ Table 5 ].
D I S C U S S I O N
Ovarian cancer is a common gynecological cancer in women and has a poor prognosis with a five-year survival rate less than 35%. International health organizations including NICE, 4 the European Society for Medical Oncology (ESMO), 14 ,15 the US Preventive Services Task Force (USPSTF), 16 and other bodies have set clinical guidelines on the recognition and management of women with ovarian cancer. These guidelines have increased the awareness towards initiating early investigations of women with suggestive symptoms and signs who present to primary care physicians. 8 Despite the high mortality of these tumors, screening asymptomatic women is still questionable and is not recommended unless the patients have known genetic mutations that increase their risk for ovarian cancer (e.g. BRCA mutations) or have suggestive clinical scenarios. 4, [14] [15] [16] In Oman, the Ministry of Health (MOH) Oman Cancer Incidence Registry (2011) showed a crude incidence ovarian cancer rate of 1.8 and an age-standardized incidence rate of 3.1 per 100,000. This took into consideration the estimated mid-year Omani population in 2011 of 2,137,807 with a sex ratio of 983 females per 1000 males. 17 No studies are available in Oman related to the incidence and whether ovarian cancer is being underdiagnosed. An audit conducted at the Royal Hospital revealed an awareness in using tumor markers effectively in Table 2 : Histological findings of the ovarian lesions in the study population. Classification includes surface epithelial-stromal (epithelial), sex cord-stromal (sex cord), and germ cell tumors (germ cell). Lesions that did not fit into any category were group "others". Secondaries include metastasis from the gastrointestinal tract and peritoneal cancers. monitoring cancer cases, including ovarian cancer, but not for diagnostic purposes. 18 Our cohort revealed a prevalence rate of malignant ovarian cancer of 15% among all surgically proven ovarian lesions for women referred to the Royal Hospital. Looking at both CA-125 and RMI as indicators for ovarian cancer [ Table 3 ], a significant difference (p<0.005) was noticed in both tools between benign and malignant groups in all sample populations as well as among the various histological types (except for sex cord lesions; p=0.094). CA-125 was raised (>35 U/ml) in 69% of women with malignant ovarian cancers and 32% of women with benign ovarian cancers. In contrast, RMI was raised (>200) in 57% of women with malignant ovarian cancers and 18% of women with benign ovarian cancers. The validity indicators of both tests [Table 4 ] showed that CA-125 has better sensitivity (69% vs. 57%) than RMI, but also has a lower specificity (68% vs. 81%). In addition, the ROC curve showed better AUC for RMI compared to CA-125 (0.771 vs. 0.745; p<0.005). The sensitivity of CA-125 and RMI was much higher when used to detect EOC (excluding the borderline cases) with values of 90% for CA-125 and 86% for RMI. Among the malignant ovarian cancer group, all women with sex cord ovarian cancer and the majority of women with borderline epithelial cancer had false negative CA-125 and RMI results. The CA-125 results also showed a high proportion of false positive results among women with endometriosis where the median CA-125 was 144 U/ml, and in one case CA-125 was raised 45 folds in a 30 years old patient who had bilateral ovarian endometriosis lesions with peritoneum involvement. However, the RMI test in this setting appears to be better than CA-125 and could identify the benign nature of ovarian endometriosis cysts in women with high CA-125 levels. Considering different cut-offs of the RMI [ Table 5 ], decreasing the index to 150 can increase its sensitivity to 62% keeping a specificity of 78%. Data obtained by different studies revealed a comparable outcome for CA-125 and RMI. [19] [20] [21] Liao et al, 22 reported in their meta-analysis of 19 studies a sensitivity and specificity of CA-125 of 75% and 80%, respectively. Currently, CA-125 is still the most widely used tumor biomarker for the detection of ovarian cancer. However, its poor specificity is considered to be the main drawback that has limited its use alone, and its incorporation in the RMI has improved its specificity. It is known that CA-125 levels can be elevated in benign gynecological conditions particularly endometriosis and fibroids, and other medical disorders such as congestive heart failure and cirrhosis. 23, 24 This limitation has facilitated researchers to look for more specific biomarkers or tools for use in this setting. The RMI can easily be adopted when assessing women with adnexal mass by utilizing both CA-125 and ultrasound, which are part of the workup investigations in these patients. In addition to CA-125 and RMI, other diagnostic tests for EOC have been recommended and evaluated. 21 These include the human epididymis protein (HE4) and the Risk of Malignancy Algorithm (ROMA) using dual CA-125 and HE4 markers. Karlsen et al, 21 reported equal performance of RMI and ROMA, despite the ROMA having a lower specificity. 21 However, Moore et al, 25 reported a higher sensitivity for ROMA than RMI for distinguishing benign status from EOC (94.3% vs. 84.6%) at a specificity of 75%. In patients with stage I and II disease, ROMA achieved a sensitivity of 85.3% compared to 64.7% for RMI. The OVA1 test is another In Vitro Diagnostic Multivariate Index Assay (IVDMIA) that has been studied in the triage of women with an adnexal mass. The assay utilizes five proteomic biomarkers: CA-125, prealbumin, apolipoprotein A1, beta-2 microglobulin, and transferrin. 26 However, in addition to the inclusion of different tests that are not routinely used in laboratory practice, this multi-marker showed comparable performance with RMI and ROMA. 
